Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

29.01B

Market cap29.01B

Price-Earnings ratio

21.03

Price-Earnings ratio21.03

Dividend yield

—

Dividend yield—

Average volume

1.02M

Average volume1.02M

High today

$199.90

High today$199.90

Low today

$196.35

Low today$196.35

Open price

$198.08

Open price$198.08

Volume

702.14K

Volume702.14K

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $196.45. The company's market cap stands at 29.01B, with a P/E ratio of 21.03.

As of 2026-06-05, Biogen(BIIB) stock has fluctuated between $196.35 and $199.90. The current price stands at $196.45, placing the stock +0.1% above today's low and -1.7% off the high.

The Biogen(BIIB)'s current trading volume is 702.14K, compared to an average daily volume of 1.02M.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.

BIIB News

Investing.com 20h

Biogen receives FDA breakthrough designation for SMA therapy - Investing.com

...

TipRanks 20h

Biogen granted Breakthrough Therapy Designation for salanersen by FDA

Biogen (BIIB) announced that the FDA has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy, or SMA. Unlock trust...

TipRanks 22h

UCB, Biogen announce dapirolizumab pegol data at EULAR

UCB and Biogen (BIIB) announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology, or EULAR, 2026 Cong...

Analyst ratings

55%

of 38 ratings

Buy

55.3%

Hold

39.5%

Sell

5.3%

More BIIB News

Simply Wall St 1d

Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen

In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosu...

Simply Wall St 6d

A Look At Biogen Valuation After Earnings Beat And Parkinson’s Setback

Biogen (BIIB) is in focus after two headline events: a first quarter 2026 earnings beat with steady revenue guidance but lower earnings expectations, and the di...

TipRanks 7d

Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors

Denali Therapeutics (DNLI), Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks P...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.